Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (4 quarters reported)
$114M in Q4 2025 → $146M now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| IT Ishares Tr | 48.3% | Unchanged | 700,000 | $70.5M |
| SS SPDR Series Trust | 41.8% | Trimmed 32% | 386,500 | $60.9M |
| Sera Prognostics Inc | 3.4% | New | 2,396,685 | $5.01M |
| Halozyme Therapeutics Inc | 0.2% | Trimmed 57% | 3,000 | $331K |
| Madrigal Pharmaceuticals Inc | 0.2% | Unchanged | 600 | $302K |
| Exelixis Inc | 0.2% | Trimmed 38% | 5,000 | $292K |
| Royalty Pharma PLC | 0.2% | Trimmed 55% | 5,000 | $292K |
| Argenx Se | 0.2% | Trimmed 53% | 300 | $288K |
| Nurix Therapeutics Inc | 0.2% | Trimmed 52% | 12,000 | $285K |
| Tg Therapeutics Inc | 0.2% | Trimmed 50% | 5,000 | $279K |
| Tarsus Pharmaceuticals Inc | 0.2% | Trimmed 50% | 3,500 | $275K |
| HB Harmony Biosciences Hldgs In | 0.2% | Trimmed 30% | 7,000 | $275K |
| Arcutis Biotherapeutics Inc | 0.2% | Trimmed 49% | 10,000 | $264K |
| KP Kiniksa Pharmaceuticals Intl | 0.2% | Trimmed 30% | 3,500 | $261K |
| Supernus Pharmaceuticals | 0.2% | Unchanged | 6,000 | $258K |
| Immunome Inc | 0.2% | Trimmed 33% | 12,000 | $258K |
| Neurocrine Biosciences Inc | 0.2% | Trimmed 40% | 1,800 | $255K |
| Oruka Therapeutics Inc | 0.2% | Unchanged | 3,000 | $250K |
| Tango Therapeutics Inc | 0.2% | Unchanged | 10,000 | $250K |
| Definium Therapeutics Inc | 0.2% | Trimmed 35% | 6,500 | $247K |
| Revolution Medicines Inc | 0.2% | Unchanged | 1,200 | $246K |
| Alkermes PLC | 0.2% | Unchanged | 6,000 | $243K |
| Aurinia Pharmaceuticals Inc | 0.2% | Trimmed 50% | 15,000 | $243K |
| Incyte Corp | 0.2% | Trimmed 62% | 2,000 | $243K |
| Intellia Therapeutics Inc | 0.2% | Unchanged | 20,000 | $241K |
| Immunovant Inc | 0.2% | Trimmed 46% | 7,000 | $236K |
| Stoke Therapeutics Inc | 0.2% | Trimmed 25% | 9,000 | $234K |
| Krystal Biotech Inc | 0.2% | Unchanged | 692 | $230K |
| Ascendis Pharma A/s | 0.2% | Trimmed 33% | 1,000 | $228K |
| Syndax Pharmaceuticals Inc | 0.2% | Trimmed 40% | 12,000 | $226K |
| Kymera Therapeutics Inc | 0.2% | Trimmed 50% | 2,000 | $224K |
| Dianthus Therapeutics Inc | 0.2% | Unchanged | 2,500 | $220K |
| Trevi Therapeutics Inc | 0.1% | Trimmed 50% | 15,000 | $215K |
| Mirum Pharmaceuticals Inc | 0.1% | Unchanged | 2,500 | $214K |
| IH Immunocore Hldgs PLC | 0.1% | Trimmed 54% | 7,000 | $212K |
| Protagonist Therapeutics Inc | 0.1% | Trimmed 50% | 1,500 | $211K |
| Edgewise Therapeutics Inc | 0.1% | Unchanged | 5,000 | $203K |
| Oric Pharmaceuticals Inc | 0.1% | Unchanged | 13,000 | $175K |
| Dyne Therapeutics Inc | 0.1% | Trimmed 50% | 10,000 | $161K |
| Compass Pathways PLC | 0.1% | Trimmed 44% | 10,000 | $124K |
| Ocular Therapeutix Inc | 0.1% | Unchanged | 15,000 | $115K |
| Cytomx Therapeutics Inc. | 0.1% | Unchanged | 39,400 | $107K |
| Ardelyx Inc | 0.1% | Trimmed 50% | 30,000 | $103K |
| Olema Pharmaceuticals Inc | 0.1% | Unchanged | 10,000 | $86.4K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.
quarter ended September 30, 2026 · filed October 21, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Series Trust | Trimmed | −183,500 | −$28.9M | 41.8% |
| Sera Prognostics Inc | New | +2,396,685 | +$5.01M | 3.4% |
| Disc Medicine Inc | Exited | −8,000 | −$585K | — |
| Rapport Therapeutics Inc | Exited | −14,000 | −$583K | — |
| UP Ultragenyx Pharmaceutical In | Exited | −17,000 | −$568K | — |
| Monte Rosa Therapeutics Inc | Exited | −23,000 | −$557K | — |
| Ionis Pharmaceuticals Inc | Exited | −6,800 | −$539K | — |
| Pharvaris N V | Exited | −15,000 | −$519K | — |
| Acadia Pharmaceuticals Inc | Exited | −19,766 | −$500K | — |
| Ptc Therapeutics Inc | Exited | −6,000 | −$489K | — |
Showing the 10 largest of 60 changes.
quarter ended June 30, 2026 · filed July 09, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Series Trust | Added | +285,100 | +$45.1M | 48.0% |
| Sera Prognostics Inc | Exited | −2,396,685 | −$4.87M | — |
| Definium Therapeutics Inc | Trimmed | −24,800 | −$1.17M | 0.3% |
| Compass Pathways PLC | Trimmed | −53,000 | −$750K | 0.1% |
| Tyra Biosciences Inc | Exited | −16,000 | −$613K | — |
| Ascendis Pharma A/s | Exited | −2,500 | −$572K | — |
| Cytokinetics Inc | Exited | −8,300 | −$547K | — |
| Agios Pharmaceuticals Inc | Exited | −15,000 | −$507K | — |
| PP Praxis Precision Medicines I | Exited | −1,500 | −$483K | — |
| Inhibrx Biosciences Inc | Exited | −6,927 | −$466K | — |
Showing the 10 largest of 57 changes.
quarter ended March 31, 2026 · filed April 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Series Trust | New | +284,900 | +$36.4M | 25.7% |
| Sera Prognostics Inc | New | +2,396,685 | +$4.87M | 3.4% |
| Definium Therapeutics Inc | New | +34,800 | +$658K | 0.5% |
| Dianthus Therapeutics Inc | Trimmed | −7,725 | −$648K | 0.3% |
| Travere Therapeutics Inc | Exited | −15,272 | −$584K | — |
| Jazz Pharmaceuticals PLC | Exited | −3,258 | −$554K | — |
| Cg Oncology Inc | Exited | −13,293 | −$552K | — |
| Belite Bio Inc | Exited | −3,443 | −$551K | — |
| Apellis Pharmaceuticals Inc | Exited | −21,866 | −$549K | — |
| Terns Pharmaceuticals Inc | Exited | −13,560 | −$548K | — |
Showing the 10 largest of 100 changes.
Loading...
